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Objective To compare increases in serum IgG antibody against pertactin with increases in
IgG against pertussis toxin and filamentous hemagglutinin (FHA) in non-vaccinated
children, children vaccinated with pertussis toxoid, and adults, all with culture-con-
firmed pertussis.
Methods During a double-blind, placebo-controlled, efficacy trial of a monocomponent
pertussis toxoid vaccine, acute and convalescent sera were obtained from study children
and family members with suspected pertussis. In the present study, IgG antibodies
against pertactin, pertussis toxin and FHA (determined by ELISA) were compared in 207
individuals with culture-verified pertussis and paroxysmal cough for 21 days.
Results Significant increases in geometric mean serum IgG against all antigens occurred
in non-vaccinated children, but more children responded against pertussis toxin and
FHA than against pertactin (96%, 97%, and 62%, respectively). Of the children who had
pertussis even though they were vaccinated with the pertussis toxoid vaccine, 97%
responded to FHA, while responses to pertussis toxin and pertactin were less common
(68% and 61%, respectively). In the 20 adults, the proportions of responders to FHA,
pertussis toxin and pertactin were 90%, 80% and 55%, respectively.
Conclusion Determination of IgG against pertussis toxin and FHA in paired sera in non-
vaccinated children with pertussis is a more sensitive diagnostic tool than determination
of IgG against pertactin. Pertactin IgG determinations might be of value as a complement
to the other antibody assays in vaccinated children and in adults.
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I N T R O D U C T I O N
Infections caused by Bordetella pertussis can be
laboratory verified by cultures from the nasophar-
ynx, detection of specific DNA with the polymer-
ase chain reaction (PCR) in nasopharyngeal
secretions, and demonstration of serum antibodies
against pertussis toxin and filamentous hemagglu-
tinin (FHA) in paired sera. Cultures have a high
specificity but a rather low sensitivity, especially in
vaccinated individuals [1–3]. PCR has a higher
sensitivity than cultures, but false-positive reac-
tions can occur [4,5]. Significant rises in serum
antibodies against pertussis toxin and FHA have
been recognized by a consensus meeting orga-
nized by the World Health Organization as being
diagnostic of pertussis [6]. The serologic assays
have a high sensitivity and specificity in non-
vaccinated individuals, but the sensitivity is lower
in individuals who have received pertussis vac-
cines containing these antigens [7,8]. All acellular
pertussis vaccines contain pertussis toxoid, and all
but one contain FHA.
The aim of the present study was to compare the
IgG antibody responses to pertactin, pertussis toxin
and FHA after culture-confirmed pertussis in non-
vaccinated children, in children vaccinated with a
monocomponent pertussis toxoid vaccine, and in
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adults vaccinated with a whole cell vaccine in
infancy.
P A T I E N T S A N D M E T H O D S
In a double-blind, placebo-controlled trial, 3450
infants were randomized to receive diphtheria–
tetanus toxoids or the same diphtheria–tetanus
toxoids combined with pertussis toxoid at three,
five and 12 months of age [3]. The study was
performed in the Go¨teborg area of western Swe-
den from 1991 through 1994. Pertussis had been
endemic in Sweden since the early 1970s. Follow-
ing changes in production around 1970, the Swed-
ish-made whole cell vaccine became ineffective [9].
When the incidence of pertussis increased despite
vaccination rates above 90%, the recommendation
to vaccinate infants against pertussis was with-
drawn in 1979 and was not reinstituted until 1996.
During the trial, nasopharyngeal secretions for
culture of B. pertussis and paired serum samples
were obtained from study children and their
family members if they had cough for 7 days.
Serum IgG antibodies against pertussis toxin and
FHA were determined in acute and convalescent
sera simultaneously as soon as the convalescent
serum arrived in the laboratory. Serum IgG anti-
bodies against pertactin were analyzed after the end
of the study on sera which had been stored frozen
at 70 8C. Aliquots which had not been thawed
were selected. The acute sera were obtained
between 7 and 14 days after onset of symptoms,
and the convalescent sera four to six weeks later.
Pertacin IgG antibodies were assayed from
patients who fulfilled all of the following criteria:
(1) isolation of B. pertussis from the nasopharynx;
(2) paroxysmal cough for 21 days; and (3) avail-
ability of serum aliquots which had not been
thawed and refrozen.
The patients included in the present study con-
sisted of four groups: (1) study children who did
not receive the pertussis toxoid vaccine (N ¼ 45,
19 male, 26 female, median age at onset of pertus-
sis two years, range one to three years); (2) non-
vaccinated siblings of study children (N ¼ 111, 51
male, 60 female, median age at onset of pertussis
four years, range 0.5–12 years); (3) study children
vaccinated with pertussis toxoid (N ¼ 31, 19 male,
12 female, median age at onset of pertussis two
years, range 0.5–four years); and (4) parents of
study children (N ¼ 20, five male, 15 female, med-
ian age at onset of pertussis 31 years, range 23–
51 years). Their history of pertussis vaccination
could not be determined, but 14 of them were
born after 1960, when coverage with the pertussis
whole cell vaccine was above 90%.
Serum IgG antibodies to pertussis toxin, FHA
and pertactin were measured by enzyme-linked
immunosorbent assay (ELISA) [3,10]. Pertussis
toxin was obtained from North American Vaccine
Inc., Beltsville, MD, USA. FHA (lot 10 000) was
obtained from Aventis Pasteur, Marcy L’Etoile,
France. Pertactin was obtained from Chiron Vac-
cines, Siena, Italy. The reference sera used were the
United States Food and Drug Administration (US
FDA) reference pertussis antisera lot 3 (for pertus-
sis toxin and FHA) and lot 4 (for pertactin). Lot 3
contained 200 units/mL of pertussis toxin IgG and
200 units/mL of FHA IgG. Lot 4 contained
90 units/mL of pertactin IgG. Sera were tested
in eight three-fold dilutions, starting with a dilu-
tion of 1 : 10. Antibody concentrations were cal-
culated with the reference line assay [11]. Sera with
IgG less than 1 unit/mL were arbitrarily assigned
a value of 0.5 units/mL. Based on studies of intra-
assay variation, an increase 2-fold was consid-
ered significant if the concentration in the conva-
lescent serum was 7 units/mL.
Comparisons of serum IgG levels between acute
and convalescent sera were made with a paired t-
test. Comparisons of proportions of individuals
with significant increases against different antigens
within groups were performed with the two-
tailed sign test using the exact binomial distribu-
tion. P-values <0.05 were considered significant.
The study was approved by the Ethics Commit-
tee of Go¨teborg University.
R E S U L T S
Tables 1 and 2 show geometric mean and median
values of IgG antibodies against the three B. per-
tussis antigens in children who were not vacci-
nated against pertussis. Geometric mean IgG
levels against all antigens increased significantly
(P < 0.001 for all antigens). Significant individual
increases in pertactin IgG antibodies were seen in
58% and 69%, respectively, in the two groups of
non-vaccinated children. These proportions were
significantly lower than those of children with
significant increases in IgG antibodies against
pertussis toxin (seen in 95% of all children) and
in IgG antibodies against FHA (seen in 97% of all
children).
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Table 1 Serum IgG antibodies against pertactin, pertussis toxin and filamentous hemagglutinin (FHA) in acute and
convalescent sera in 45 children who participated in the vaccine efficacy trial and were not vaccinated against pertussis
Pertactin Pertussis toxin FHA
Acute Convalescent Acute Convalescent Acute Convalescent
Geometric mean 6 27 1 221 2 97
Median 4 33 <1 >400 2 139
Minimum 1 1 <1 5 <1 3
Maximum 284 369 202 >400 10 >400
Number with
sign increase
26/45a 43/45b 42/45c
aversus, bP ¼ 0.00008; aversus, cP ¼ 0.00003.
Table 2 Serum IgG antibodies against pertactin, pertussis toxin and filamentous hemagglutinin (FHA) in acute and
convalescent sera in 111 non-vaccinated siblings of study children who participated in the vaccine efficacy trial
Pertactin Pertussis toxin FHA
Acute Convalescent Acute Convalescent Acute Convalescent
Geometric mean 13 49 1 193 3 152
Median 14 50 <1 >400 2 164
Minimum 1 1 <1 4 <1 13
Maximum 193 >400 >400 >400 >400 >400
Number with
sign increase
71/111a 106/111b 109/111c
aversus, bP < 0.00001; aversus, cP < 0.00001.
Table 3 Serum IgG antibodies against pertactin, pertussis toxin and filamentous hemagglutinin (FHA) in acute and
convalescent sera in 31 study children who participated in the vaccine efficacy trial and were vaccinated with pertussis
toxoid
Pertactin Pertussis toxin FHA
Acute Convalescent Acute Convalescent Acute Convalescent
Geometric mean 14 37 28 127 2 121
Median 11 37 32 140 2 134
Minimum 2 7 <1 20 <1 33
Maximum 208 344 >400 >400 35 >400
Number with
sign increase
19/31a 21/31b 30/31c
aversus, cP ¼ 0.003.
Table 4 Serum IgG antibodies against pertactin, pertussis toxin and filamentous hemagglutinin (FHA) in acute and
convalescent sera in 20 adults with pertussis
Pertactin Pertussis toxin FHA
Acute Convalescent Acute Convalescent Acute Convalescent
Geometric mean 25 63 19 215 35 212
Median 24 86 39 335 27 227
Minimum 4 7 <1 28 5 42
Maximum 82 >400 >400 >400 355 >400
Number with
sign increase
11/20a 16/20b 18/20c
aversus, cP ¼ 0.039.
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In children who contracted pertussis despite
vaccination with the pertussis toxoid vaccine
(Table 3), levels of pertussis toxin IgG anti-
bodies were already high in the acute serum,
which led to a lower proportion of significant
increases against this antigen (68%). Significant
increases against FHA, which the children were
not exposed to previously, were seen in 97% of the
children, which was significantly higher than the
proportion of children with pertactin IgG increases
(61%).
In the 20 adults (Table 4), the proportion with
significant increases against FHA was higher than
the proportion with significant increases against
pertactin, while the differences when compared
with pertussis toxin IgG were not significant.
D I S C U S S I O N
Pertactin is, like FHA, an outer-membrane protein
of B. pertussis and B. parapertussis [12]. Serum anti-
body responses to pertactin have been demonstra-
ted both in patients with pertussis and in patients
with parapertussis [13,14]. Other organisms prob-
ably have proteins which, to a certain extent, cross-
react with pertactin and with FHA, since low
levels of serum antibodies to these proteins have
been detected in patients who have no history of
bordetella infections and who are not vaccinated
with these antigens [15,16]. Pertussis toxin, which
is a protein exotoxin, is specific for B. pertussis, and
no cross-reacting antigens are known.
The results of the present study showed, in
agreement with another study from our group
[10] as well as a study from Germany [13], that
significant increases in geometric mean pertactin
IgG serum antibodies occur in non-vaccinated
children with pertussis but that a substantial num-
ber of children fail to mount an antibody response,
which makes pertactin IgG serology less sensitive
than pertussis toxin and FHA IgG serology. Per-
tactin IgG antibody determinations in paired sera,
may, however, be used as a supplement to other
serologic assays in vaccinated children and in
adults with pertussis. Pertussis toxin serology is
less sensitive in children vaccinated with this anti-
gen, because previous exposure to the antigen
results in a rapid booster response, with high
IgG levels already being present in the acute
serum. This makes it more difficult to demonstrate
significant antibody increases, as shown in the
present and a previous study [8]. The same seems
to be true for FHA serology in paired sera in
children vaccinated with an acellular pertussis
vaccine containing this antigen [7].
In conclusion, pertactin IgG increases in the
majority of non-vaccinated children with pertus-
sis, but significant IgG increases against pertactin
are less common than increases against pertussis
toxin and FHA. Pertactin IgG antibody determina-
tions in individuals with suspected pertussis can-
not replace pertussis toxin and FHA antibody
determinations, but may represent a complement
to these assays in vaccinated individuals.
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